Edges in Network
| Network | GSE5851_top8000 - GSE5851 - SiGN-BN NNSR |
| Network Description | Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC |
| Node | CD2 |
| Upstream (Parents) |
|---|
| (<<) HLA-DMB → CD2 |
| (<<) CCL5 → CD2 |
| (<<) TRBC1///TRBC2 → CD2 |
| (<<) TRBC1 → CD2 |
| (<<) PPP1R16B → CD2 |
| Downstream (Children) |
|---|
| CD2 → PLA2G2D (>>) |
| CD2 → CXCL9 (>>) |
| CD2 → CXCL10 (>>) |
| CD2 → TRAT1 (>>) |
| CD2 → SIRPG (>>) |
| CD2 → ICOS (>>) |
| CD2 → HLA-DOB (>>) |
| CD2 → CD3G (>>) |
| CD2 → UBASH3A (>>) |
| CD2 → PTPRCAP (>>) |
| CD2 → CCL5 (>>) |
| CD2 → IDO1 (>>) |
| CD2 → TRBC1///TRBC2 (>>) |
| CD2 → P2RY10 (>>) |
| CD2 → IL16 (>>) |
| CD2 → PRKCB (>>) |
| CD2 → CD6 (>>) |
| CD2 → ACAP1 (>>) |
| CD2 → TRBC1 (>>) |
| CD2 → RASGRP1 (>>) |
| CD2 → BATF (>>) |
| CD2 → CD3E (>>) |
